CN109562088A - 用于治疗和预防自身免疫病的代谢物 - Google Patents

用于治疗和预防自身免疫病的代谢物 Download PDF

Info

Publication number
CN109562088A
CN109562088A CN201780049297.2A CN201780049297A CN109562088A CN 109562088 A CN109562088 A CN 109562088A CN 201780049297 A CN201780049297 A CN 201780049297A CN 109562088 A CN109562088 A CN 109562088A
Authority
CN
China
Prior art keywords
individual
acid
diet
chain fatty
nod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780049297.2A
Other languages
English (en)
Chinese (zh)
Inventor
查尔斯·雷伊·麦凯
埃利安娜·马里诺·莫雷诺
特雷弗·洛基特
朱莉·克拉克
大卫·托平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Monash University
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903143A external-priority patent/AU2016903143A0/en
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO, Monash University filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of CN109562088A publication Critical patent/CN109562088A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pediatric Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780049297.2A 2016-08-10 2017-08-10 用于治疗和预防自身免疫病的代谢物 Pending CN109562088A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016903143A AU2016903143A0 (en) 2016-08-10 Metabolites for treatment of autoimmune disease
AU2016903143 2016-08-10
PCT/AU2017/050845 WO2018027274A1 (en) 2016-08-10 2017-08-10 Metabolites for treatment and prevention of autoimmune disease

Publications (1)

Publication Number Publication Date
CN109562088A true CN109562088A (zh) 2019-04-02

Family

ID=61160999

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780049297.2A Pending CN109562088A (zh) 2016-08-10 2017-08-10 用于治疗和预防自身免疫病的代谢物

Country Status (8)

Country Link
US (3) US20190167615A1 (enExample)
EP (1) EP3496708B1 (enExample)
JP (1) JP7097027B2 (enExample)
CN (1) CN109562088A (enExample)
AU (1) AU2017310263B2 (enExample)
CA (1) CA3070939A1 (enExample)
ES (1) ES3029611T3 (enExample)
WO (1) WO2018027274A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
AU2019358875B2 (en) * 2018-10-09 2025-08-21 Monash University Combination therapy for treatment and prevention of autoimmune and inflammatory diseases
CN109771404A (zh) * 2019-02-28 2019-05-21 北京大学人民医院(北京大学第二临床医学院) 丁酸在制备预防和/或治疗自身免疫性疾病药物中的应用
EP3838283A1 (en) * 2019-12-18 2021-06-23 Mundus Sanus GmbH & Co. KG Composition for use in the treatment of provocative diseases
US20230190942A1 (en) * 2020-06-03 2023-06-22 Corn Products Development, Inc. Compositions of tri-substituted starch and methods for making and using the same
CN115068458B (zh) * 2022-07-21 2023-12-12 哈尔滨医科大学 戊酸在制备防治糖尿病药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039703A (en) * 1989-11-16 1991-08-13 Breuer Richard I Method for treating inflammatory bowel disorders
US5840860A (en) * 1993-11-17 1998-11-24 Commonwealth Scientific And Industrial Research Organization Fatty acid delivery system comprising a hydrolyzable bond
CN101316598A (zh) * 2005-09-28 2008-12-03 甜糖（曼海姆/奥克森富特）股份公司 碳水化合物和糖类多羟基化合物的丁酸酯
WO2015066433A1 (en) * 2013-10-31 2015-05-07 Sloan-Kettering Institute For Cancer Research Methods and compositions for inducing regulatory t-cell generation
US20160136122A1 (en) * 2014-10-16 2016-05-19 Jose U. Scher Methods for treating psoriatic arthritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ132599A0 (en) 1999-07-01 1999-07-22 Commonwealth Scientific And Industrial Research Organisation Nasogastric enteral formulations
WO2014145970A1 (en) * 2013-03-15 2014-09-18 President And Fellows Of Harvard College Modulation of regulatory t cells via g-coupled protein receptor 43
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US11065217B2 (en) * 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
AU2019358875B2 (en) * 2018-10-09 2025-08-21 Monash University Combination therapy for treatment and prevention of autoimmune and inflammatory diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039703A (en) * 1989-11-16 1991-08-13 Breuer Richard I Method for treating inflammatory bowel disorders
US5840860A (en) * 1993-11-17 1998-11-24 Commonwealth Scientific And Industrial Research Organization Fatty acid delivery system comprising a hydrolyzable bond
CN101316598A (zh) * 2005-09-28 2008-12-03 甜糖（曼海姆/奥克森富特）股份公司 碳水化合物和糖类多羟基化合物的丁酸酯
WO2015066433A1 (en) * 2013-10-31 2015-05-07 Sloan-Kettering Institute For Cancer Research Methods and compositions for inducing regulatory t-cell generation
US20160136122A1 (en) * 2014-10-16 2016-05-19 Jose U. Scher Methods for treating psoriatic arthritis

Also Published As

Publication number Publication date
JP2019527714A (ja) 2019-10-03
EP3496708C0 (en) 2025-03-26
AU2017310263A1 (en) 2019-02-07
WO2018027274A1 (en) 2018-02-15
ES3029611T3 (en) 2025-06-27
EP3496708A4 (en) 2020-04-01
CA3070939A1 (en) 2018-02-15
US20190167615A1 (en) 2019-06-06
US20210244692A1 (en) 2021-08-12
EP3496708B1 (en) 2025-03-26
JP7097027B2 (ja) 2022-07-07
EP3496708A1 (en) 2019-06-19
US20250295617A1 (en) 2025-09-25
AU2017310263B2 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
US20250295617A1 (en) Metabolites for treatment and prevention of autoimmune disease
Fu et al. The role of intestinal microbes on intestinal barrier function and host immunity from a metabolite perspective
Freitag et al. Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease
US12257272B2 (en) Method and system for reducing the likelihood of developing depression in an individual
US11273187B2 (en) Method and system for reducing the likelihood of developing depression in an individual
CN110049760B (zh) 用于治疗炎性疾病的组合物及其用途以及益生菌组合物
Liu et al. In vitro effects of tartary buckwheat-derived nanovesicles on gut microbiota
US20240024382A1 (en) Method and System to Modify an Individual's Gut-Brain Axis to Provide Neurocognitive Protection
CN102947441A (zh) 来自拟杆菌属的细胞组分、其组合物和使用拟杆菌或其细胞组分的治疗方法
Bech-Nielsen et al. Manipulation of the gut microbiota in C57BL/6 mice changes glucose tolerance without affecting weight development and gut mucosal immunity
AU2019201644A1 (en) Probiotic formulations and methods for use
van der Kleij et al. Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve
CN108883140A (zh) 治疗1型糖尿病的组合物和方法
JP2017535597A (ja) 障害の微生物的処置および診断に関する方法および組成物
KR20210000758A (ko) 당뇨병 및 장 질환의 치료 또는 예방에 사용하기 위한 파에칼리박테리움 프라우스니치이 및 데설포비브리오 피거
JP6840272B2 (ja) 細菌株を含む組成物
FR2962045A1 (fr) Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires
US12318414B2 (en) Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
JP2021118687A (ja) 新規のビフィドバクテリウムビフィダム菌株及び菌株由来多糖体
US20220202866A1 (en) Milk derived extracellular vesicles for use in treating inflammatory bowel disease
WO2024139107A1 (zh) 毛螺菌科微生物菌株、预防或治疗肿瘤的药物及应用
AU2020257267A1 (en) Compositions including novel microbes with enhanced persistence, synergistic combinations of novel microbes and prebiotics, and methods for the isolation of such microbes
Liu et al. Intestinal bacteria encapsulated by biomaterials enhance immunotherapy
Hume et al. The pathogenesis of Crohn's disease in the 21st century
JP2022523701A (ja) 内臓痛の予防および／または処置のためのラクトコッカス・ラクティス株

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190402